Ambeed.cn

首页 / / / c-Met/HGFR / JNJ-38877605

JNJ-38877605 {[allProObj[0].p_purity_real_show]}

货号:A275907

JNJ-38877605 is an ATP-competitive inhibitor of c-Met with IC50 of 4 nM.

JNJ-38877605 化学结构 CAS号:943540-75-8
JNJ-38877605 化学结构
CAS号:943540-75-8
JNJ-38877605 3D分子结构
CAS号:943540-75-8
JNJ-38877605 化学结构 CAS号:943540-75-8
JNJ-38877605 3D分子结构 CAS号:943540-75-8
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

JNJ-38877605 纯度/质量文件 产品仅供科研

货号:A275907 标准纯度: {[allProObj[0].p_purity_real_show]}
批次查询: 批次纯度:

全球学术期刊中引用的产品

Nat. Biomed. Eng., 2024, 8, 1412-1424. Ambeed. [ A538667 , A631746 ]
JMC, 2024. Ambeed. [ A833302 , A475501 , A341986 , A356070 ]
BMC Cancer, 2024, 24(1): 1415. Ambeed. [ A809692 , A209020 ]
J. Am. Soc. Mass Spectrom., 2024, 35(12): 3192-3202. Ambeed. [ A166127 , A902473 , A753371 , A961334 , A292945 , A230770 , A300620 , A1114580 , A1159765 , A206238 ]
PloS One, 2024, 19(11): e0308060. Ambeed. [ A302917 ]
更多 >

JNJ-38877605 生物活性

描述 The receptor tyrosine kinase c-Met, also known as receptor of hepatocyte growth factor (HGF) and scatter factor, plays an important role in physiologic processes such as embryologic development, wound healing, tissue regeneration, angiogenesis, cell growth, local invasion, and morphogenetic differentiation[3]. And its downstream v-akt murine thymoma viral oncogene homolog (AKT) and mitogen-activated protein kinase (ERK) pathways are regulated by HGF/c-MET. The HGF/c-MET axis is involved in cancer progression, metastasis, and acquired resistance[4]. JNJ-38877605 is an orally available, nanomolar active and highly selective c-Met ATP-competitive kinase inhibitor with IC50 of 4.7 nM for c-Met kinase, which induces cell death in tumor cells overexpressing c-MET protein or expressing constitutively activated c-MET protein, and it also can suppress the phosphorylation of Ron[5]. After JNJ-38877605 totally was dosed 200, 300 and 350 mg/kg per week for 1 month at rabbits, renal toxicity had been observed[6]. In an experiment, a kind of deuterated JNJ-38877605 was administrated 10 mg/kg to cynomolgus monkeys, suggesting that deuterated JNJ-38877605 displayed diminished renal toxicity[7]. In a vitro study, EBC1 (NSCLCs), GTL16, NCI-H1993, and MKN45 (gastric adenocarcinomas) cell lines were treated with c-Met selective inhibitor JNJ-38877605 at a dose of 500 nM for 2h, as it is expected that JNJ-38877605 caused a significant reduction of Met phosphorylation[5]. In a vivo study, JNJ-3887760 were used to treat renal CSCs (cancer stem cells) mice implanted with a human bone at a dose of 40 mg/kg for 60 days, and it was showed that JNJ-38877605 inhibited the activation of osteoclasts induced by RCC stem cells and it stimulated osteoblast activity, finally resulting in a reduction of bone turnover consistent with the inhibition of bone metastases[8].
作用机制 JNJ-38877605 binds to the ATP-binding site of c-Met kinase with a high affinity.

JNJ-38877605 细胞研究

细胞系 浓度 检测类型 检测时间 活动说明 数据源
human EBC1 cells Proliferation assay 72 h Antiproliferative activity against human EBC1 cells after 72 hrs, IC50=9.5 nM 26005523
human MKN45 cells Proliferation assay 72 h Antiproliferative activity against human MKN45 cells after 72 hrs, IC50=10.9 nM 26005523
human SNU5 cells Proliferation assay 72 h Antiproliferative activity against human SNU5 cells after 72 hrs, IC50=15.8 nM 26005523
mouse BAF3/TPR-Met cells Proliferation assay 72 h Antiproliferative activity against mouse BAF3/TPR-Met cells after 72 hrs, IC50=17.6 nM 26005523

JNJ-38877605 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT00651365 Neoplasms Phase 1 Terminated(Early termination d... 展开 >>ue to increase in serum creatinine levels and minimal PD activity.) 收起 << - -

JNJ-38877605 参考文献

[1]Torti D, Sassi F, et al. A preclinical algorithm of soluble surrogate biomarkers that correlate with therapeutic inhibition of the MET oncogene in gastric tumors. Int J Cancer. 2012 Mar 15;130(6):1357-66.

[2]De Bacco F, Luraghi P, et al. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. J Natl Cancer Inst. 2011 Apr 20;103(8):645-61.

[3]Gentile A, Trusolino L, Comoglio PM. The Met tyrosine kinase receptor in development and cancer. Cancer Metastasis Rev. 2008 Mar;27(1):85-94. doi: 10.1007/s10555-007-9107-6. PMID: 18175071.

[4]Aoyama A, Katayama R, Oh-Hara T, Sato S, Okuno Y, Fujita N. Tivantinib (ARQ 197) exhibits antitumor activity by directly interacting with tubulin and overcomes ABC transporter-mediated drug resistance. Mol Cancer Ther. 2014 Dec;13(12):2978-90. doi: 10.1158/1535-7163.MCT-14-0462. Epub 2014 Oct 13. PMID: 25313010.

[5]Benvenuti S, Lazzari L, Arnesano A, Li Chiavi G, Gentile A, Comoglio PM. Ron kinase transphosphorylation sustains MET oncogene addiction. Cancer Res. 2011 Mar 1;71(5):1945-55. doi: 10.1158/0008-5472.CAN-10-2100. Epub 2011 Jan 6. PMID: 21212418.

[6]Lolkema MP, Bohets HH, Arkenau HT, Lampo A, Barale E, de Jonge MJA, van Doorn L, Hellemans P, de Bono JS, Eskens FALM. The c-Met Tyrosine Kinase Inhibitor JNJ-38877605 Causes Renal Toxicity through Species-Specific Insoluble Metabolite Formation. Clin Cancer Res. 2015 May 15;21(10):2297-2304. doi: 10.1158/1078-0432.CCR-14-3258. Epub 2015 Mar 5. PMID: 25745036; PMCID: PMC4433755.

[7]Zhan Z, Peng X, Sun Y, Ai J, Duan W. Evaluation of Deuterium-Labeled JNJ38877605: Pharmacokinetic, Metabolic, and in Vivo Antitumor Profiles. Chem Res Toxicol. 2018 Nov 19;31(11):1213-1218. doi: 10.1021/acs.chemrestox.8b00191. Epub 2018 Oct 16. PMID: 30284817.

[8]D'Amico L, Belisario D, Migliardi G, Grange C, Bussolati B, D'Amelio P, Perera T, Dalmasso E, Dalle Carbonare L, Godio L, Comoglio P, Trusolino L, Ferracini R, Roato I. C-met inhibition blocks bone metastasis development induced by renal cancer stem cells. Oncotarget. 2016 Jul 19;7(29):45525-45537. doi: 10.18632/oncotarget.9997. PMID: 27322553; PMCID: PMC5216739.

JNJ-38877605 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.65mL

0.53mL

0.27mL

13.25mL

2.65mL

1.33mL

26.50mL

5.30mL

2.65mL

JNJ-38877605 技术信息

CAS号943540-75-8
分子式C19H13F2N7
分子量 377.35
别名
运输蓝冰
存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Inert atmosphere,Store in freezer, under -20°C

溶解度

DMSO: 30 mg/mL(79.5 mM),注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

动物实验配方

30% propylene glycol+5% Tween 80+65% water 30 mg/mL suspension

Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
  • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务,不为任何个人或者非科研性质用途提供服务。